A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment.

Trial Details

NCT ID
NCT06435429
Phase
PHASE3
Sponsor
Jazz Pharmaceuticals
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Zanidatamab
  • Trastuzumab
  • Eribulin
  • Vinorelbine
  • Gemcitabine
  • Capecitabine
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Cerritos, California, United States|33.85835,-118.06479
  • Los Angeles, California, United States|34.05223,-118.24368
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637

Key Eligibility Criteria

  • Is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form …
  • Participants are excluded from the study if any of the following criteria apply:
  • Medical Conditions
  • Has clinically confirmed leptomeningeal disease, in the opinion of the investigator.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →